RTW Investments LP has recently announced that it has increased stake in Relmada Therapeutics Inc. (NASDAQ:RLMD) by 0.26%. After grabbing 2.64 million shares, the institutional investor is now in possession of 6894.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.80% having worth around $16.9 million. Moreover, Deep Track Capital LP increased its share by 2.02 million to have a control over 2.48 million shares. And Perceptive Advisors LLC raised its holdings to 2.26 million shares by acquiring 2.38 million shares or 7.93% of the stake.
Relmada Therapeutics Inc. (RLMD) concluded trading on 12/08/22 at a closing price of $2.17, with 7.09 million shares of worth about $15.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -88.40% during that period and on Thursday the price saw a loss of about -47.84%. Currently the company’s common shares owned by public are about 30.06M shares, out of which, 29.70M shares are available for trading.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the RLMD stock and their offered price forecasts bring an average price target of $18.50. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $42.00 and could fall to a lowest price of $3.00. The stock’s current price level is 87.54% above of average price target set by the analysts, while a rise to estimated low would result in gain of 27.67% for the stock. However, touching the estimated high of $42.00 would mean a gain of 94.83% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 17 times over the past 12 months. They bought 59,567 shares in 4 of the transactions. In 13 selling transactions, insiders dumped 79,567 shares.
Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Relmada Therapeutics Inc. Vanguard Total Stock Market Index is currently holding 0.9 million shares of worth totaling $5.78 million. The company recently came buying 0.0 shares which brought its stake up to 3.01% of the company’s outstanding shares. iShares Russell 2000 ETF sold 11235.0 shares, after which its hold over company’s outstanding shares shrunk to 2.01%, leaving 0.6 million shares with the mutual fund that have a worth of about $3.85 million. Vanguard Extended Market Index Fu, after buying 0.35 million shares, have now control over 1.18% of the stake in the company. It holds 1344.0 shares of worth $2.26 million.
Relmada Therapeutics Inc. (NASDAQ: RLMD) started trading at $2.45, below -$1.71 from concluding price of the previous day. However, the stock later moved at a day high price of 2.4850, or with a loss of -47.84%. Stock saw a price change of -52.83% in past 5 days and over the past one month there was a price change of -63.83%. Year-to-date (YTD), RLMD shares are showing a performance of -90.37% which decreased to -88.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.09 but also hit the highest price of $38.68 during that period. The average intraday trading volume for Relmada Therapeutics Inc. shares is 1.13 million. The stock is currently trading -58.97% below its 20-day simple moving average (SMA20), while that difference is down -82.25% for SMA50 and it goes to -89.77% lower than SMA200.
RTW Investments LP acquired 2.64 million shares of Relmada Therapeutics Inc. having value of about $16.9 million. Data submitted at the U.S SEC by RTW Investments LP revealed that the firm now holds 6894.0 shares in the company valued at close to $14959.98, or have control over 0.26% stake in the company. Relmada Therapeutics Inc. (NASDAQ: RLMD) currently have 30.06M outstanding shares and institutions hold larger chunk of about 86.90% of that. Holding of mutual funds in the company is about 15.78% while other institutional holders and individual stake holders have control over 75.15% and 1.54% of the stake respectively.
The stock has a current market capitalization of $65.34M and its 3Y-monthly beta is at -0.01. It has posted earnings per share of -$5.84 in the same period. It has Quick Ratio of 9.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RLMD, volatility over the week remained 12.09% while standing at 9.06% over the month.
Analysts are in expectations that Relmada Therapeutics Inc. (RLMD) stock would likely to be making an EPS of -$1.45 in the current quarter, while forecast for next quarter EPS is -$1.43 and it is -$3.87 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.65 which is -$1.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2.44 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -87.90% while it is estimated to increase by 29.80% in next year.
Analysts at 6 brokerage firms have issued recommendations for the Relmada Therapeutics Inc. (RLMD)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.60. Out of those 6 Wall Street analysts, 2 recommended a “Buy” rating, while 4 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on October 14, 2022 offering a Hold rating for the stock and assigned a target price range of between $90 and $10 to it. On October 14, 2022, Goldman Downgrade their recommendations, while on October 13, 2022, Oppenheimer Downgrade their ratings for the stock with a price target of $7. Stock get a Buy rating from Mizuho on November 18, 2021.
